Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) was the target of a significant increase in short interest in the month of May. As of May 15th, there was short interest totalling 43,800 shares, an increase of 17.1% from the April 30th total of 37,400 shares. Approximately 0.4% of the company’s shares are short sold. Based […]
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) saw a significant growth in short interest in May. As of May 15th, there was short interest totalling 43,800 shares, a growth of 17.1% from the April 30th total of 37,400 shares. Based on an average trading volume of 48,000 shares, the short-interest ratio is presently 0.9 days. […]
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) major shareholder Caissa Capital Management Ltd. bought 13,121 shares of the firm’s stock in a transaction on Thursday, May 18th. The stock was acquired at an average price of $3.29 per share, for a total transaction of $43,168.09. Following the completion of the purchase, the insider now directly […]
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) major shareholder Caissa Capital Management Ltd. bought 7,000 shares of the business’s stock in a transaction that occurred on Monday, May 22nd. The stock was purchased at an average price of $3.34 per share, with a total value of $23,380.00. Following the completion of the purchase, the insider […]
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) major shareholder Caissa Capital Management Ltd. acquired 13,121 shares of the business’s stock in a transaction that occurred on Thursday, May 18th. The stock was acquired at an average cost of $3.29 per share, with a total value of $43,168.09. Following the completion of the acquisition, the insider […]